Cost-analysis of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal malignancy: An Australian perspective with global application

Autor: Cherry E. Koh, Daniel Steffens, Kate E. McBride, Brendan Moran, Nabila Ansari, Christopher J. Young, Michael J. Solomon
Rok vydání: 2020
Předmět:
Male
medicine.medical_specialty
Financing
Government
Operating Rooms
Multivariate analysis
Critical Care
Total cost
Health Personnel
Operative Time
Hyperthermic Intraperitoneal Chemotherapy
030230 surgery
Tertiary referral hospital
Peritoneal malignancy
03 medical and health sciences
0302 clinical medicine
Medicine
Humans
Hospital Costs
Activity-based costing
health care economics and organizations
Diagnostic Techniques and Procedures
Peritoneal Neoplasms
Aged
Retrospective Studies
business.industry
Hospitals
Public
Australia
General Medicine
Cytoreduction Surgical Procedures
Length of Stay
Middle Aged
Oncology
030220 oncology & carcinogenesis
Emergency medicine
Cost analysis
Costs and Cost Analysis
Surgery
Hyperthermic intraperitoneal chemotherapy
Female
Clinical Competence
business
Cytoreductive surgery
Learning Curve
Zdroj: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 47(4)
ISSN: 1532-2157
Popis: Cost-effective cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of patients with peritoneal malignancy remains an ongoing financial challenge for healthcare systems, hospitals and patients. This study aims to describe the detailed in-hospital costs of CRS and HIPEC compared with an Australian Activity Based Funding (ABF) system, and to evaluate how the learning curve, disease entities and surgical outcomes influence in-hospital costs.A retrospective descriptive costing review of all CRS and HIPEC cases undertaken at a large public tertiary referral hospital in Sydney, Australia from April 2017 to June 2019. In-hospital cost variables included staff, critical care, diagnosis, operating theatre, and other costs. Univariate and multivariate analyses were conducted to investigate the differences between actual cost and the provision of funding, and potential factors associated with these costs.Of the 118 CRS and HIPEC procedures included in the analyses, the median total cost was AU$130,804 (IQR: 105,744 to 153,972). Provision of funding via the ABF system was approximately one-third of the total CRS and HIPEC costs (p 0.001). Surgical staff proficiency seems to reduce the total CRS and HIPEC costs. Surgical time, length of intensive care unit and hospital stay are the main predictors of total CRS and HIPEC costs.Delivery of CRS and HIPEC is expensive with high variability. A standard ABF system grossly underestimates the specific CRS and HIPEC funding required with supplementation essential to sustaining this complex highly specialised service.
Databáze: OpenAIRE
Externí odkaz: